September 29, 2008 – NeoGenomics Laboratories (OTCBB: NGNM), a national clinical reference laboratory specializing in high-complexity, cancer-specific testing, announced an exclusive agreement with
Response Genetics Inc. (Nasdaq: RGDX) to offer its proprietary ResponseDX: Colon™ and ResponseDX: Lung™ tests nationwide. ResponseDX: Colon™ and ResponseDX: Lung™ are proprietary PCR-based tests in a cost-effective panel format which serve to help oncologists make optimal therapeutic treatment decisions for patients with colorectal cancer (CRC) and non-small cell lung cancer (NSCLC)... [PDF] NeoGenomics Laboratories' Press Release -
